Stock ALPMY ASTELLAS PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Astellas Pharma Inc. Stock OTC Markets

Equities

ALPMY

US04623U1025

Pharmaceuticals

Delayed OTC Markets
Other stock markets
 03:06:08 2024-05-30 pm EDT 		5-day change 1st Jan Change
9.686 USD +0.37% Intraday chart for Astellas Pharma Inc. -1.76% -18.61%
May. 21 Astellas Announces Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies CI
May. 16 Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea DJ

Financials

Sales 2024 1,604B 10.23B Sales 2025 * 1,676B 10.69B Capitalization 2,725B 17.39B
Net income 2024 17.04B 109M Net income 2025 * 81.86B 522M EV / Sales 2024 1.63 x
Net Debt 2024 336B 2.14B Net Debt 2025 * 479B 3.06B EV / Sales 2025 * 1.91 x
P/E ratio 2024
173 x
P/E ratio 2025 *
33.7 x
Employees 14,484
Yield 2024
4.26%
Yield 2025 *
4.85%
Free-Float 98.84%
More Fundamentals * Assessed data

Chart Astellas Pharma Inc.

Dynamic Chart

Latest news about Astellas Pharma Inc.

Astellas Announces Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies CI
Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea DJ
Astellas Unveils New, State-Of-The-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor CI
Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos MT
Malin Corp investee signs agreement with Astellas Pharma AN
Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences DJ
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion RE
Transcript : Astellas Pharma Inc., 2024 Earnings Call, Apr 25, 2024
Astellas Pharma Inc. Declares Year End Dividend for the Year Ended March 31, 2023 and Provides Interim and Year End Dividend Guidance for the Fiscal Year 2024 CI
Astellas Pharma Inc. Provides Consolidated Earnings Guidance on Full Basis for the Full-Year 2024 CI
Astellas Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Astellas Pharma Inc. Announces Board and Committee Retirements CI
European Commission Approves Astellas Pharma Label Extension for Xtandi MT
Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting CI
Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs MT
More news

Latest transcript on Astellas Pharma Inc.

Logo Astellas Pharma Inc.
Astellas Pharma Inc., 2024 Earnings Call, Apr 25, 2024
More transcripts

Analyst Recommendations on Astellas Pharma Inc.

Jefferies Adjusts Astellas Pharma’s Price Target to 2,100 Yen From 2,200 Yen, Keeps at Buy MT
Jefferies Adjusts Astellas Pharma’s Price Target to 2,200 Yen From 2,400 Yen, Keeps at Buy MT
Jefferies Upgrades Astellas Pharma to Buy From Hold, Keeps Price Target at 2,400 Yen MT
Jefferies Adjusts Astellas Pharma's Price Target to 2,400 Yen From 2,300 Yen, Keeps at Buy MT
Jefferies Adjusts Astella Pharma’s Price Target to 2,300 Yen From 2,200 Yen, Keeps at Buy MT
More recommendations

Press releases Astellas Pharma Inc.

Astellas Confirms Unfavorable District Court Decision Concerning its Motion for a Preliminary Injunction against Lupin and Zydus Generic Versions of MyrbetriqTM AQ
U.S. FDA Accepts Astellas' Supplemental New Drug Application for IZERVAY (avacincaptad pegol intravitreal solution) for Geographic Atrophy AQ
Astellas VYLOY Approved in Japan for Treatment of Gastric Cancer AQ
Iveric Bio - Astellas Receives Permanent J-code for IZERVAY for Geographic Atrophy AQ
Astellas Receives Positive CHMP Opinion for XTANDI in Additional Recurrent Early Prostate Cancer Treatment Setting AQ
More press releases

News in other languages on Astellas Pharma Inc.

MÄRKTE ASIEN/Freundlich - Yen lotet neue Tiefs aus
MIDDAY BRIEFING - Unternehmen und Märkte
MÄRKTE ASIEN/Börsen stecken Eskalation im Nahen Osten gut weg
Aktien Asien/Pazifik: Eskalation im Nahen Osten drückt die Kurse - CSI legt zu
Bayer plant Zulassungsantrag für neues Mittel gegen Wechseljahrsbeschwerden
More news

Quotes and Performance

1 week-2.13%
Current month+1.05%
1 month+1.05%
3 months-13.45%
6 months-20.64%
Current year-18.91%
More quotes

Highs and lows

1 week
9.62
Extreme 9.62
10.05
1 month
9.42
Extreme 9.42
10.30
Current year
9.15
Extreme 9.15
12.71
1 year
9.15
Extreme 9.15
16.64
3 years
9.15
Extreme 9.15
18.46
5 years
9.15
Extreme 9.15
18.46
10 years
9.15
Extreme 9.15
19.40
More quotes

Managers and Directors - Astellas Pharma Inc.

Managers TitleAgeSince
Naoki Okamura CEO
 Chief Executive Officer 61 86-03-31
Kitamura Atsushi DFI
 Director of Finance/CFO 52 Oct. 31
Kenji Yasukawa CHM
 Chairman 63 86-03-31
Members of the board TitleAgeSince
Takashi Tanaka BRD
 Director/Board Member 67 21-05-31
Mamoru Sekiyama BRD
 Director/Board Member 74 17-05-31
Kenji Yasukawa CHM
 Chairman 63 86-03-31
More insiders

Quotes

Date Price Change Volume
24-05-30 9.686 +0.37% 547 474
24-05-29 9.65 -2.53% 243,492
24-05-28 9.9 -0.90% 525,485
24-05-24 9.99 +1.32% 410,404
24-05-23 9.86 +1.54% 297,250

Delayed Quote OTC Markets, May 30, 2024 at 10:14 am EDT

More quotes

Company Profile

Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders. Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).
Sector
Pharmaceuticals
Calendar
2024-05-30 - American Society of Clinical Oncology Meeting - Abstract Number : e23287
Related indices
Nikkei 225
More about the company

Income Statement Evolution

More financial data

Ratings for Astellas Pharma Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
1,536 JPY
Average target price
1,966 JPY
Spread / Average Target
+28.01%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+39.03% 731B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.22% 586B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.89% 348B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.53% 319B
ABBVIE INC. Stock AbbVie Inc.
-0.32% 273B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.72% 235B
ROCHE HOLDING AG Stock Roche Holding AG
-6.71% 203B
NOVARTIS AG Stock Novartis AG
+7.52% 202B
AMGEN INC. Stock Amgen Inc.
+3.06% 159B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4503 Stock
  4. ALPMY Stock